Segall Bryant & Hamill LLC Reduces Holdings in Pediatrix Medical Group, Inc. (NYSE:MD)

Segall Bryant & Hamill LLC reduced its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 5.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 1,244,950 shares of the company’s stock after selling 74,289 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Pediatrix Medical Group were worth $14,429,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of MD. Quest Partners LLC boosted its stake in shares of Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after purchasing an additional 622 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Pediatrix Medical Group by 3.5% during the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock worth $245,000 after acquiring an additional 1,088 shares during the last quarter. ProShare Advisors LLC grew its stake in Pediatrix Medical Group by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock worth $170,000 after acquiring an additional 1,167 shares during the period. Nisa Investment Advisors LLC raised its holdings in Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares during the last quarter. Finally, SummerHaven Investment Management LLC lifted its stake in shares of Pediatrix Medical Group by 3.8% during the 2nd quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock worth $422,000 after purchasing an additional 2,069 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Insider Activity

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,808 shares of company stock worth $751,277. 2.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

MD has been the topic of several recent analyst reports. Truist Financial increased their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. StockNews.com downgraded shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating in a report on Thursday. Mizuho lifted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, UBS Group upped their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, Pediatrix Medical Group currently has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Trading Down 0.8 %

Shares of MD stock opened at $14.49 on Thursday. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The firm’s 50 day moving average price is $12.77 and its two-hundred day moving average price is $9.96. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -4.74, a price-to-earnings-growth ratio of 2.03 and a beta of 1.55. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. During the same period in the prior year, the company earned $0.29 EPS. The firm’s revenue was up .9% on a year-over-year basis. On average, analysts anticipate that Pediatrix Medical Group, Inc. will post 1.25 EPS for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.